Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Bolstering Neuroscience Portfolio

Acquisition Details:
Johnson & Johnson (J&J) has entered into a definitive agreement to acquire Intra-Cellular Therapies, Inc. for $132.00 per share in cash, totaling approximately $14.6 billion in equity value15.

Portfolio Enhancement:
The acquisition includes CAPLYTA (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy, and for the treatment of schizophrenia in adults15.

Future Potential:
A supplemental New Drug Application (sNDA) has been submitted to the U.S. FDA for CAPLYTA as an adjunctive treatment for major depressive disorder, which could make it a standard of care for common depressive disorders15.

Pipeline:
The acquisition also includes ITI-1284, a promising Phase 2 compound being studied in generalized anxiety disorder (GAD) and Alzheimer’s disease-related psychosis and agitation, further complementing J&J’s current areas of focus15.

Strategic Growth:
This acquisition is part of J&J’s strategic effort to strengthen its neuroscience leadership and expand its portfolio in neuropsychiatric and neurodegenerative disorders15.

Long-term Impact:
The deal is expected to serve as a strategic near- and long-term growth catalyst for J&J, offering compelling value to patients, health systems, and shareholders15.

Sources:

1. https://www.jnj.com/media-center/press-releases/johnson-johnson-strengthens-neuroscience-leadership-with-acquisition-of-intra-cellular-therapies-inc

5. https://www.biospace.com/press-releases/johnson-johnson-strengthens-neuroscience-leadership-with-acquisition-of-intra-cellular-therapies-inc